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Abstract
BACKGROUND: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids
derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties.
It is widely used in the treatment of acute ischaemic stroke in Russia, China, and other Asian
and post-Soviet countries. OBJECTIVES: To assess the benefits and risks of Cerebrolysin for
treating acute ischaemic stroke. SEARCH METHODS: We searched the Cochrane Stroke Group
Trials Register (October 2014), the Cochrane Central Register of Controlled Trials (CENTRAL)
(November 2014), MEDLINE (1966 to November 2014), EMBASE (1974 to November 2014), Web
of Science Core Collection, with Science Citation Index (1940 to November 2014), LILACS (1982
to December 2014), OpenGrey (1980 to December 2014), and a number of Russian Databases
(1998  to  December  2014).  We also  searched  reference  lists,  ongoing  trials  registers  and
conference proceedings, and contacted the manufacturer of Cerebrolysin, EVER Neuro Pharma
GmbH (formerly Ebewe Pharma). SELECTION CRITERIA: Randomised controlled trials comparing
Cerebrolysin started within 48 hours of stroke onset and continued for at least two weeks with
placebo  or  no  treatment  in  people  with  acute  ischaemic  stroke.  DATA  COLLECTION  AND
ANALYSIS: Two review authors independently applied inclusion criteria, assessed trial quality
and risk  of  bias,  and extracted data.  MAIN RESULTS:  We included one trial  involving 146
participants. We evaluated risk of bias and judged it to be high for generation of allocation
sequence, low for allocation concealment, high for incomplete outcome data (attrition bias),
unclear  for  blinding,  high  for  selective  reporting  and  high  for  other  sources  of  bias.  The
manufacturer of Cerebrolysin, pharmaceutical company Ebewe, provided Cerebrolysin and the
placebo, as well as the randomisation codes. There was no difference in the number of deaths
(6/78 in Cerebrolysin group versus 6/68 in placebo group; risk ratio (RR) 0.87, 95% confidence
interval (CI) 0.29 to 2.58) or in the total number of adverse events (16.4% versus 10.3%; RR
1.62,  95%  CI  0.69  to  3.82)  between  the  treatment  and  control  groups.  AUTHORS'
CONCLUSIONS: Routine administration of Cerebrolysin to people with acute ischaemic stroke
cannot be supported by the available evidence from RCTs.
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